BIOMAT Database Logo BIOMAT Database Logo

Cholesterol embolization syndrome following thrombolytic therapy with streptokinase and tissue plasminogen activator. 1994

S Ben-Chitrit, and Z Korzets, and R Hershkovitz, and J Bernheim, and M Schneider, and J Bernheim
Dept. of Internal Medicine B, Meir General Hospital, Kfar Saba, Israel.

UI MeSH Term Description Entries
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D010959 Tissue Plasminogen Activator A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases. Alteplase,Plasminogen Activator, Tissue-Type,T-Plasminogen Activator,Tissue-Type Plasminogen Activator,Actilyse,Activase,Lysatec rt-PA,TTPA,Tisokinase,Tissue Activator D-44,Lysatec rt PA,Lysatec rtPA,Plasminogen Activator, Tissue,Plasminogen Activator, Tissue Type,T Plasminogen Activator,Tissue Activator D 44,Tissue Type Plasminogen Activator
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D013300 Streptokinase Streptococcal fibrinolysin . An enzyme produced by hemolytic streptococci. It hydrolyzes amide linkages and serves as an activator of plasminogen. It is used in thrombolytic therapy and is used also in mixtures with streptodornase (STREPTODORNASE AND STREPTOKINASE). EC 3.4.-. Avelizin,Awelysin,Celiase,Distreptase,Kabikinase,Kabivitrum,Streptase,Streptodecase
D015912 Thrombolytic Therapy Use of infusions of FIBRINOLYTIC AGENTS to destroy or dissolve thrombi in blood vessels or bypass grafts. Fibrinolytic Therapy,Thrombolysis, Therapeutic,Therapeutic Thrombolysis,Therapy, Fibrinolytic,Therapy, Thrombolytic,Fibrinolytic Therapies,Therapeutic Thrombolyses,Therapies, Fibrinolytic,Therapies, Thrombolytic,Thrombolyses, Therapeutic,Thrombolytic Therapies
D017700 Embolism, Cholesterol Blocking of a blood vessel by CHOLESTEROL-rich atheromatous deposits, generally occurring in the flow from a large artery to small arterial branches. It is also called arterial-arterial embolization or atheroembolism which may be spontaneous or iatrogenic. Patients with spontaneous atheroembolism often have painful, cyanotic digits of acute onset. Atheroembolism,Cholesterol Embolism,Atheroembolisms,Cholesterol Embolisms,Embolisms, Cholesterol

Related Publications

S Ben-Chitrit, and Z Korzets, and R Hershkovitz, and J Bernheim, and M Schneider, and J Bernheim
Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity.
August 1988, Blood,
S Ben-Chitrit, and Z Korzets, and R Hershkovitz, and J Bernheim, and M Schneider, and J Bernheim
Quantitation of fragment X formation during thrombolytic therapy with streptokinase and tissue plasminogen activator.
June 1987, The Journal of clinical investigation,
S Ben-Chitrit, and Z Korzets, and R Hershkovitz, and J Bernheim, and M Schneider, and J Bernheim
Tissue plasminogen activator and cholesterol crystal embolization.
October 1989, Annals of internal medicine,
S Ben-Chitrit, and Z Korzets, and R Hershkovitz, and J Bernheim, and M Schneider, and J Bernheim
[Thrombolytic therapy with tissue-type plasminogen activator].
July 1994, Nihon rinsho. Japanese journal of clinical medicine,
S Ben-Chitrit, and Z Korzets, and R Hershkovitz, and J Bernheim, and M Schneider, and J Bernheim
Cholesterol embolization after treatment with tissue plasminogen activator.
November 1989, The New England journal of medicine,
S Ben-Chitrit, and Z Korzets, and R Hershkovitz, and J Bernheim, and M Schneider, and J Bernheim
Thrombolytic therapy: a review of the literature on streptokinase and tissue plasminogen activator with implications for practice.
June 1989, Critical care nursing clinics of North America,
S Ben-Chitrit, and Z Korzets, and R Hershkovitz, and J Bernheim, and M Schneider, and J Bernheim
Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.
May 1995, The New England journal of medicine,
S Ben-Chitrit, and Z Korzets, and R Hershkovitz, and J Bernheim, and M Schneider, and J Bernheim
Acylated plasminogen-streptokinase activator complex: a new approach to thrombolytic therapy.
January 1990, Pharmacotherapy,
S Ben-Chitrit, and Z Korzets, and R Hershkovitz, and J Bernheim, and M Schneider, and J Bernheim
Future indications for thrombolytic therapy with tissue plasminogen activator.
January 1989, Journal of emergency nursing,
S Ben-Chitrit, and Z Korzets, and R Hershkovitz, and J Bernheim, and M Schneider, and J Bernheim
[Selective thrombolytic therapy with a tissue activator of plasminogen].
January 1985, Medicina,
Copied contents to your clipboard!